Triple-Negative Breast Cancer
Advertisement
Trodelvy plus Keytruda improves PFS in first-line PD-L1+ mTNBC, marking a first for a TROP-2 ADC-immunotherapy combination.
Sacituzimab govitecan showed modest CNS activity in pretreated HER2-negative metastatic breast cancer with brain metastases.
Shorter chemoimmunotherapy shows promise in early TNBC, with higher pCR in PD-L1+ or TIL-high patients, Neo-N trial finds.
Adding atezolizumab to chemotherapy did not result in clinical benefit in patients with triple-negative breast cancer.
Researchers aimed to evaluate the roll of ERCC1 expression in predicting response to adjuvant chemotherapy for TNBC.
A novel method can assess which patients with TNBC could benefit from immunotherapy.
New research shows that selenium, a mineral commonly found in Brazil nuts, could hold the key to stopping the spread of TNBC.
Cancer researchers at Brigham and Women’s Hospital have identified a potential new method for the treatment of TNBC.
New research suggests ICI therapy improves efficacy outcomes in early-stage breast cancer over adjuvant therapy.
Dr. Margaret Gatti-Mays explains how to address the most pressing questions in triple-negative breast cancer treatments.
Dr. Gatti-Mays discusses how treatment for triple-negative breast cancer has evolved in recent years.
Dr. Margaret Gatti-Mays, who specializes in breast cancer, delivers key insights on many breast cancer-related topics.
Soft tumor environments can cause triple-negative breast cancer to spread more aggressively.
A researcher is looking to prove that nebivolol, an FDA-approved drug for high blood pressure, is effective at treating TNBC.
For patients with breast cancer, a regimen of epirubicin followed by adjuvant chemotherapy is associated with worse QOL.
Drs. Vishwas Paralkar and Sophia Gayle discuss CBX-15, a novel therapy for triple-negative breast cancer.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.